Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now. - Barron's
1. Biotech sector shows renewed strength, with XBI up 23% in three months. 2. Merck recently acquired Verona Pharma, illustrating biotech acquisition trends. 3. Large pharmaceutical companies are responding to thinning pipelines through acquisitions. 4. Gilead Sciences trading just 5% below its 52-week high showcases market resilience. 5. Royalty Pharma indicates potential growth amid biotech resurgence.